

Disclaimer

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME *Essential Areas and Elements, Policies, and Standards for Commercial Support* as well as the ACPE *Criteria for Quality and Interpretive Guidelines*. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

■ Participating Faculty

Peter Alagona Jr, MD, FACC

Associate Professor of Medicine and Radiology
Pennsylvania State College of Medicine
Program Director General Cardiology
Pennsylvania State Heart and Vascular Institute
Hershey, Pennsylvania

Mark J. Cziraky, PharmD, CLS, FAHA

Vice President, Research Development and Operations
HealthCore, Inc
Wilmington, Delaware
Adjunct Assistant Professor
Philadelphia College of Pharmacy
University of the Sciences in Philadelphia
Philadelphia, Pennsylvania

■ Faculty Disclosures

Peter Alagona Jr, MD, FACC

Honoraria:

Abbott
Merck–Schering-Plough
Pfizer

Mark J. Cziraky, PharmD, CLS, FAHA

Grant Support (on behalf of HealthCore, Inc):

Abbott
AstraZeneca
Bristol-Myers Squibb
Pfizer

The faculty members disclose that this activity discusses the unapproved/off-label use of fibrates and niacin in combination therapy with statins.

Faculty Disclosures

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CE activity disclose any relevant affiliation or other financial relationship (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation, and (2) with any commercial supporters of the activity. Conflict resolution must occur prior to the CE activity. The ACHL also requires participating faculty to disclose when unapproved/unlabeled uses of a product are discussed in a CE activity.

Staff Disclosures

The Academy for Continued Healthcare Learning staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Cost-Effectiveness and Outcome Optimization Strategies in the Treatment of Residual Cardiovascular Risk Beyond LDL Cholesterol in the Managed Care Setting

Release date: March 15, 2009
Expiration date: March 15, 2010

Intended Audience

This activity is intended for pharmacists and other healthcare professionals interested in managing patients with dyslipidemia.

Activity Purpose

This educational activity will discuss residual cardiovascular risk remaining after statin therapy. Evidence will be presented on the role of combination therapies for optimizing lipid control. Recent health economics and outcomes research data on the impact of residual cardiovascular risk on healthcare costs will be presented, as will modeling studies that address short-term and lifetime cost estimates of various pharmacologic interventions targeting cardiovascular risk.

Learning Objectives

Upon completion of this activity, participants will:

- Evaluate the economic impact of untreated residual cardiovascular risk in patients with suboptimal lipid values based on current epidemiologic trends and treatment patterns
- Analyze the costs and outcomes associated with treatments for the management of lipid parameters, including high-density lipoprotein cholesterol and triglycerides, in various member populations
- Apply the presented health plan-level data from various patient populations to select appropriate treatments for residual cardiovascular disease risk as a way of improving disease management, leading to potentially improved outcomes and cost savings

Method of Participation

It has been determined that this activity can be completed in 1 hour(s). The participant should review the learning objectives and faculty disclosures, review the materials, reflect on the content, answer the posttest questions, and complete the enrollment/evaluation forms. To earn credit, a minimum score of 70% must be achieved on the posttest. A certificate of credit will be mailed to participants within 6 weeks of receipt of mailed or faxed forms. (Certificates will be immediately available if the completed posttest and forms are submitted online at www.ajmc.com/LDL.) There is no fee to participate in the program or for the generation of the certificate.

Accreditation

Accreditation is provided by The Academy for Continued Healthcare Learning.

Pharmacists



The Academy for Continued Healthcare Learning (ACHL) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. In order to receive credit, pharmacists must complete the activity requirements and evaluation at the conclusion of the program. This activity has been approved for a maximum of 0.1 CEU. ACPE Universal Program Number (UPN): 396-000-08-057-H01-P

Sponsored by **The Academy for Continued Healthcare Learning**

Supported by an educational grant from **Solvay Pharmaceuticals** and **Abbott**